The p53 gene is frequently mutated in cancers and it is vital for cell cycle control, homeostasis and carcinogenesis. We describe a novel p53 mutational spectrum, different to those generally observed in human and murine tumors. Our study shows a high prevalence of nonsense mutations in the p53 N terminus of 2-acetylaminofluorene (2-AAF)-induced urinary bladder tumors. These nonsense mutations forced downstream translation initiation at codon 41 of Trp53, resulting in the aberrant expression of the p53 isoform DN-p53 (or p44). We propose a novel mechanism for the origination and the selection for this isoform. We show that chemical exposure can act as a novel cause of selection for this truncated protein. In addition, our data suggest that the occurrence of DN-p53 accounts, at least in mice, for a cancer phenotype. We also show that gene expression profiles of embryonic stem (ES) cells carrying the DN-p53 isoform in a p53-null background are divergent from p53 knockout ES cells, and therefore postulate that DN-p53 itself has functional transcriptional properties.
Introduction
The tumor suppressor p53 regulates significant cellular functions to prevent the initiation and prolongation of cancer and is intensively studied. Several isoforms of p53 have been identified (Courtois et al., 2002; Candeias et al., 2006; Grover et al., 2009; Marcel and Hainaut, 2009) , and point mutations influencing the functionality of p53 were elucidated and mimicked in vivo (de Vries et al., 2002; Wijnhoven et al., 2005; Hoogervorst et al., 2005a; Iwakuma and Lozano, 2007; Heinlein et al., 2008) . The p53 gene is the most frequently mutated gene in cancer and analysis of many different human tumor types have shown a high prevalence of missense mutations located primarily in the central DNA-binding domain (Levine, 1997) . Frequently, these mutations result in the expression of mutant p53 proteins, which are often more stable than wild-type p53 (Hailfinger et al., 2007) . A small variety of isoforms, which lack an N-terminal and/or C-terminal part of the protein, have been discovered (Courtois et al., 2002; Marcel and Hainaut, 2009) , and can result in a dominant-negative inhibition of the wild-type p53 protein (de Vries et al., 2002) . However, a gain-of-function phenotype of mutant p53, which enhances the oncogenic properties of p53, has also been proposed (Strano et al., 2007; Xu, 2008) .
To gain more functional insight into p53 and the effect of alterations in its gene, several transgenic mouse models have been generated (Lozano, 2007) . For example, the Trp53 þ /À model appears to be more susceptible than wild-type mice to carcinogenesis, both spontaneous and chemically induced (Hoogervorst et al., , 2005b . We have previously investigated the effect of p53 heterozygosity to the exposure of the carcinogen 2-acetylaminofluorene (2-AAF), a strong inducer of urinary bladder tumors . As stress signals like DNA damage can affect p53 function, we also investigated Trp53 þ /À in combination with a deficiency in the DNA repair gene Xpa. Carcinogenesis in both models is putatively caused by Trp53 mutations in the remaining wild-type allele, shown by the presence of mutated p53 protein in early atypical preneoplastic lesions and tumors . Here, we reveal a mutational spectrum in tumors divergent from that generally observed after carcinogen exposure (http://p53.free.fr/index.html). A high frequency of predominantly N-terminal nonsense mutations was found in the Trp53 gene, resulting in the selective expression of an N-terminally truncated p53-isoform (DN-p53). We further investigated the impact of this isoform by creating and analyzing embryonic stem (ES) cells harboring a nonsense mutation at codon 5, expressing the DN-p53 isoform. We showed that this isoform has functional transcriptional properties that differ from both wild-type and p53 knockout cells.
Results

P53 mutational analysis in urinary bladder tumors
In our previous study and Xpa À/À /Trp53 þ /À mice with the CM5 antibody and the Pab240 antibody (data not shown) to identify positive mutant p53 tumor fields. Sequence analysis of exons 2-8 was carried out on DNA isolated from both mutant p53-positive and -negative tumor fields. The DNA sequence results are summarized in Table 1 and mutational hotspots are depicted in Figure 1 .
In total, 78% of the examined urinary bladder tumors (21 out of 27) harbored a mutation in the Trp53 gene. A wide variety of Trp53 mutations was observed (Table 1) . The majority of mutations identified were single base changes found in Trp53 DNA. Mutations were confirmed at the mRNA level, indicating that p53 transcripts were stable even though many of them carried a translational stop codon at the 5 0 region of the transcript. The mutations comprised predominantly G:C-T:A transversions (28 out of 36 single base mutations ¼ 78%), consistent with the mutations frequently found after 2-AAF exposure (Vousden et al., 1986; Ross and Leavitt, 1998) . In compliance with previous exposure studies, 61% of the mutations found in the DNA-binding domain (exons 4-8) were missense mutations (14 from 23).
Of the single base mutations, 53% (19 out of 36) were nonsense mutations. Of these, a relatively high percentage (11 out of 19 ¼ 63%) was found between codons 1 and 41 of the N-terminal part of the p53 protein. To illustrate this significant bias (P ¼ 0.0011, w 2 test): six of the 10 (60%) possible G:C-T:A transversion target sites (amino acids that can be changed into a nonsense codon by a G:C-T:A transversion) 
Abbreviation: 2-AAF, 2-acetylaminofluorene. upstream of codon 41, were found mutated in the tumor set analyzed in this study. In contrast, only seven out of 51 (14%) (possible) stop codon targets were found mutated in the remaining part of the p53 protein (Table 1 and Figure 1 ). In addition, some of these nonsense mutations were present more frequently for a few codons (Table 1) . These nonsense mutations at the 5 0 end of the Trp53 gene accounted for 31% (11 out of 36) of the total number of single base p53 mutations found. Clearly, a selection of nonsense mutations at the extreme 5 0 end of the p53 gene seems to occur after 2-AAF exposure.
No p53 protein was detectable by immunohistochemistry in tumors carrying a nonsense mutation present downstream of codon 41 (data not shown). However, when staining was performed on a selection of tumors containing nonsense codons upstream of codon 41 (codons 5, 14 and 23 were investigated), the presence of p53 protein was still observed, as was shown by immunohistochemistry analyses using both CM5 ( Figure 2c ) and Pab240 antibody (staining not shown). These tumor fields did not, however, show staining with the 1C12 antibody (Figure 2d ), only recognizing the N-terminal part of the p53 protein. Therefore, an altered version of the p53 protein appears to be present lacking some amino-acid residues at the N terminus (Figure 2 ).
Functional analysis of nonsense mutations at the 5 0 end of Trp53 in ES cells A downstream ATG site in the Trp53 sequence is present at codon 41, surrounded by sequences that match the Kozak consensus criteria (Kozak, 1984) . This codon may, therefore, act as an alternative translational start site, which may explain the exhibited absence of 1C12 antibody staining of mutant p53 protein in tumors carrying specific N-terminal stop codons.
To provide evidence for this hypothesis, we generated two different knockin mutant ES cell lines. The targeting constructs were introduced into a p53-null cell line. In one cell line, we introduced a TAG translational stop at codon 5 (stop5), mimicking the p53 mutation found in the 2-AAF-induced bladder tumors ( Figure 3a and Supplementary Figure 1A) . In a second cell line, this TAG stop codon was complemented with a mutation at codon 41, in which this presumptive alternative translational start codon ATG was replaced by an ATA (Ile encoding) codon (stop5 and ATA41; Figure 3a and Supplementary Figure 1B Selection of a functional DN-p53 isoform JPM Melis et al blot, but could theoretically still be present in very low amounts. Additional replacement of the alternative start codon 41 eliminated the translation of DN-p53 completely ( Figure 3b , lane 5), leading to the conclusion that this variant protein indeed originates from translational initiation at codon ATG41. Western blotting ( Figure 3b ) and quantitative-PCR analysis of Trp53 (data not shown) on these two knock-in mutant genotypes showed that the DN-p53 variant isoform originates from a stable transcript. Transcripts from the double mutant (stop5 and ATA41), however, appeared to be unstable, only 4% steady-state levels, as compared to wild type, were observed. This again supports our view that the ATG41 is used as a start signal for translation, which leads to stabilization of the transcript.
Transcriptomics in ES cells carrying the DN-p53 protein
Subsequently, gene expression profiles of ES cells with various genotypes were analyzed to examine the functional impact of the p53 isoform and to investigate whether it showed differences with a p53 knockout genotype. The genotypes studied included wild type Figures 4b and c) when compared with the transcriptionally significant regulated single genes in Figure 4a . These results together indicate that DN-p53 isoform does in some way reacts similar to the knockout genotype, and also shows aberrant regulation in several pathways and gene sets. Thirty-nine GO terms (cat. 3, Figure 4b ) seem to be divergently regulated only in Trp53 stop5/À when compared with wild type, and not when the knockout is compared with wild type. Among these are several developmental processes, plus the GO terms extracellular space, angiogenesis and actin filament binding. C2 analysis resulted in 88 gene sets (cat. 3, Figure 4c ), which are only significantly regulated in the Trp53 stop5/À compared with wild-type cells. A full overview of the GO and C2 analyses is shown in the Supplementary Table 1 .
We subsequently conducted whole genome GO and C2 analyses (Po0.005 and FDR ¼ 0.1) between the Trp53 À/À and the Trp53 stop5/À genotypes to further elucidate the differences between the two (see Supplementary Table 2 for a full overview). The GO analysis shows 10 pathways differentially and significantly regulated between the two genotypes (Table 2a) , whereas 82 gene sets are aberrantly regulated. Seven out of the 10 GO terms overlap with those shown in Figure 4b , and are, therefore, even stronger significantly upregulated in Trp53 stop5/À
. Again, collagen and extracellular matrix pathways are more regulated in Trp53 stop5/À when compared with the knockout ES cells. The 82 differential C2 gene sets contain several gene sets, which are linked to cancer, growth, invasiveness and tumor growth factor-b signaling pathways. Of these gene sets, 48 were present in the overlapping 210 gene sets in Figure 4c , which means they were already significantly differential from wild type in both p53 impaired ES cells. A selection of gene sets is shown in Table 2b . In addition, Supplementary Table 3 shows a selection of single genes, most of which are involved in the pathways and gene sets mentioned in Table 2 .
Discussion
P53 is the most commonly mutated gene in mammalian tumors (Lim et al., 2009) . Its role as a tumor suppressor in the prevention of cancer is multifaceted, as the p53 protein interacts with and transactivates a wide variety of key proteins. P53-deficient organisms show a strong increase in the rate of tumor onset and subsequently in the development of multiple tumor types (Hollstein et al., 1991; Levine et al., 1991; Matheu et al., 2008) .
In this study, 2-AAF induced urinary bladder tumors in Trp53 þ /À and Xpa
mutations. Single base mutations, predominantly in specific G:C-T:A transversions, were found. In agreement with other studies (Sigal and Rotter, 2000; Soussi, 2007) , we found several missense mutations in the DNA-binding domain. Interestingly, however, a high percentage of nonsense mutations were present predominantly at the 5 0 end of the Trp53 gene. There is a significant selection (P ¼ 0.0011, w 2 test) for these N-terminal nonsense mutations found in the bladder tumors induced after 2-AAF exposure.
Immunohistochemical staining confirmed that p53 protein was present in the tumor cells, but the protein lacked the N-terminal domain. Using homologous recombination experiments in ES cells, we showed that codon 41 is used as a novel start site when a nonsense mutation is present at codon 5. This is most likely also the case for the other nonsense mutation variants we found located upstream of codon 41 (Table 1) . The manner in which this 'forced' isoform translation takes place owing to the 5 0 nonsense mutations is unknown and needs further investigation. Previous reports have shown that internal ribosomal entry sites can play a role and can be phase dependent on the cell cycle (Ray et al., 2006b; Grover et al., 2009) . Another option might be that translational leakage occurs and 'false' initiation takes place at codon 41, which is surrounded by a Kozak consensus sequence (Kozak, 1984) .
The existence of DN-p53 has already been reported (Courtois et al., 2002; Maier et al., 2004) , but up to now it was not known that selectively induced N-terminal stop mutations could be the origin of this p53 isoform. Unlike many other studies that have only focused on sequencing the DNA-binding domain (exons 4-8), our studies characterized exons 2-8 of the Trp53 gene. This could be one of the reasons why these specific 5 0 end stop mutations went undetected until now. In addition, bladder tumors are not among the most commonly found tumor types.
Previously, it was shown that DN-p53 originates from alternative splicing events (Yin et al., 2002; Ghosh et al., 2004) or occurs as a natural isoform (Courtois et al., 2002; Ray et al., 2006a) . Courtois et al. (2002) proposed that alternative translation initiation at codon 41 was stop5/À and Trp53 À/À genotypes were also discovered. Several developmental and regulatory processes, together with pathways involved in extracellular space, angiogenesis and actin filament binding are expressed at higher levels in Trp53 stop5/À cells than in p53 knockout cells. The same holds when GO term analysis was applied, processes involved in the formation of the extracellular matrix and the production of collagen are expressed at higher levels in Trp53 stop5/À cells than Trp53 À/À cells (Table 2a) . These pathways are also found upregulated in invasive tumors and are known to be involved in metastasis (Pupa et al., 2002; Denys et al., 2009 ). In addition, gene sets (Table 2b) and  single genes (Supplementary Table 3) , which are correlated with cancer, growth, invasiveness, metastasis and tumor growth factor-b signaling are significantly regulated in an increased manner in Trp53 stop5/À ES cells when compared with knockout cells.
The effects on gene expression were all examined in ES cells and suggest that Trp53 stop5/À cells have a distinct phenotype compared with Trp53 À/À cells. However, the selective outcome of exposure to 2-AAF was seen in epithelial bladder tissue. For a fair characterization of the functional effect of DN-p53, an in vivo analysis is more suitable. We, therefore, are currently creating mouse models that transcribe the isoform of p53 in different genotypical backgrounds (Trp53
). Exposure of these models to 2-AAF and/ or other stressors should shed more light on the origin, selection and function of the p53 isoform. In addition, it cannot be excluded that the gene expression profiles of wild-type and Trp53 stop5/À cells are also influenced by splice variants of Trp53. Some splice variants of Trp53, which are present in normal cells might also occur for the DN-p53 isoform; therefore, the expression profiles could be the result of a combined expression, although western blotting shows no additional other sized proteins.
In conclusion, our data suggest that the N-terminal truncated p53 isoform can originate upon genotoxic stress owing to the introduction of selective nonsense mutations in the p53 gene. In addition, this study provides evidence that the transcriptional activity in cells expressing the DN-p53 isoform is functionally divergent from p53 knockout cells and may lead to a even more malignant phenotype and possibly has some gain-of-function properties.
Materials and methods
Induction of urinary bladder tumors 2-AAF-induced urinary bladder tumors in Trp53 þ /À and Xpa
þ /À mice were obtained from our previously reported study . Briefly, mice were treated for 39 weeks with 300 p.p.m. 2-AAF in the diet. Liver, spleen and urinary bladder were collected at autopsy and fixed in 3.8% formaldehyde. The formaldehyde-fixed samples were embedded in paraffin wax, cut into 5-mm sections and stained with hematoxylin and eosin.
Immunohistochemical detection of p53 protein P53 protein accumulation was detected in paraffin-embedded, formalin-fixed sections from urinary bladder tumors. Polyclonal CM5 antibody, which recognizes several epitopes of both wild-type and mutant mouse p53 protein (Novocastra, Newcastle upon Tyne, UK), the Pab240 antibody specific for mutant p53 protein (Labvision, Freemont, CA, USA) and the 1C12 antibody (Cell Signaling, Danvers, MA, USA) recognizing the N-terminal part of the p53 protein, were used (previously described by Hoogervorst et al., 2004) . The level of CM5, Pab240 and 1C12 staining was scored by dividing the area of p53-positive fields by the total area of the tumor Â 100% and the final result was scored either negative (À; p5%) or positive ( þ ; X5%).
Trp53 mutation analyses by DNA and cDNA sequencing Formalin-fixed, paraffin-embedded urinary bladder tumors were analyzed for Trp53 mutations by direct sequencing of genomic DNA. P53-positive and -negative fields were marked on the p53-stained slides. Tumor regions were isolated on an adjacent 14-mm section slides. Genomic DNA was isolated with the QIAamp DNA minikit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. The coding region of the Trp53 gene, spanning from exons 2 to 8 was amplified using the HotStarTaq Master Mix Kit (Qiagen) and a dedicated set of primers (Supplementary Figure 2, primer set 1). Subsequently, exon 2, exons 3 and 4, exons 5 and 6 plus exons 7 and 8 were reamplified by using primer set 2 (Supplementary Figure 2) .
Frozen bladder tumor sections were analyzed for Trp53 mutations by RT-PCR. RNA was isolated with TRIzol reagent (Invitrogen, Breda, The Netherlands) as described by the manufacturer's protocol. For RT-PCR, performed with the Titan One Tube RT-PCR System (Roche, Woerden, The Netherlands), the primers used are depicted in Supplementary  Figure 2 , primer set 3. Subsequently, exons 2-5, exons 5 and 6, exons 7 and 8 and exons 9-11 were reamplified by using the primers of primer set 4 (Supplementary Figure 2) .
Purified PCR products (QIAquick PCR Purification Kit; Qiagen) were directly sequenced using the Big Dye Terminator Sequence kit version 3.1 (Applied Biosystems, Carlsbad, CA, USA) and an ABI 3700 DNA sequencer, with identical primers as used for reamplification PCR. Figure 1) . The mutations lead to a glutamic acid-to-stop and a methionine-to-isoleucine substitution at codons 5 and 41, respectively. Primer set 5 was used to introduce the mutations into the Trp53 sequence (Supplementary Figure 2) .
The targeting vectors (Figure 3 and Supplementary Figure  1) were constructed by cloning the mutated fragment into flanking genomic p53 fragments comprising intron 4-3 0 end of the gene (Wijnhoven et al., 2005) together with the transcriptional stop cassette described by Olive et al. (2004) . This stop cassette contains a puromycin selection marker flanked by LoxP sites. Targeting vectors contained a pGK-DTA selection marker (kindly provided by F Gertler, Massachusetts Institute of Technology, Cambridge, MA, USA) at the 3 0 end of the vector for negative selection.
Homologous recombination experiments in ES cells. The targeting vectors (Figure 3 and Supplementary Figure 1) were linearized and electroporated into p53 À/À D3 ES cells (kindly provided by Prof. T Jacks, MIT, Cambridge, MA, USA) using standard procedures (Jacks et al., 1994) . Puromycin-resistant ES cell clones were analyzed for correct homologous integration of the targeting vector by Southern blot analysis (Supplementary Figure 1) . Recombination was examined by using an exon 1 probe (previously described in Jacks et al., 1994) (EcoR1-Stu1 digestion) and a 1.3-kb probe spanning exons 7-9 (BamH1 digestion). Correctly targeted ES cell clones were expanded and electroporated with circular pMC-CreN plasmid (kindly provided by F Alt, Harvard Medical School, Boston, MA, USA). Clones that had lost the selectable marker cassette were selected for, by adding puromycin to the culture medium. Correctly targeted clones that were used for blastocyst injection procedures or cellular assays were analyzed for additional (undesired) mutations.
Western blot analyses
Protein analyses were executed as described previously (Bruins et al., 2004) . Western blotting was performed with CM5 anti-p53 rabbit polyclonal antibody (Novacastra). Primary antibodies were detected by incubating with horse radish peroxidaselinked donkey anti-rabbit immunoglobulin G (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) and staining was carried out using ECL-plus reagent (Amersham Pharmacia Biotech). Actin protein levels, detected by a horse radish peroxidase-linked anti-actin affinity-purified goat polyclonal antibody (I-19; Santa Cruz, Santa Cruz, CA, USA), were determined by a loading control.
Microarray analysis
Wild-type, Trp53 stop5/À and Trp53 À/À ES cells were cultured as a monoculture for 26 h (using a 0.1% gelatin coating, no feeder layers were used to prevent mixed-cell-type sampling). Proliferation rates of all the four genotypes (including the p53.E5stop.M41I variant) were in the same range and were examined by XTT test (Roche) (results not shown). Total RNA was isolated using the RNeasy Mini Kit (Qiagen). RNA quality was tested using automated gel electrophoresis (Bioanalyzer 2100; Agilent Technologies, Amstelveen, the Netherlands). All RNA samples used had an RNA integrity number 49.9.
RNA samples (wild-type Trp53 þ / þ , Trp53 stop5/À , Trp53 À/À : n ¼ 5 per genotype) were labeled and hybridized to Mouse GeneChip 430 2.0 (Affymetrix, Santa Clara, CA, USA) according to manufacturer's protocol. Owing to technical quality control, one Trp53 À/À sample was discarded as a technical outlier.
The microarray data were normalized by robust multichip average (Irizarry et al., 2003) using a custom chip definition files as described by de Leeuw et al. (2008) . Of the hybrid probe set definitions included in the annotation, 16.331 probe sets (http://brainarray.mbni.med.umich.edu/Brainarray/Database/ CustomCDF) and the 4.648 Affymetrix probe sets corresponding to an Entrez Gene ID were used in further analysis. Subsequent data analyses were performed using R (R Development Core Team, 2008) , Microsoft Excel and GeneMaths (Sint-Martens-Latem, Belgium). Log-transformed gene expression values were compared between a pair of two groups using a Welch's t-test, and genes with a P-value o0.001 and a fold ratio (defined as maximum/minimum average group value) 41.5 were considered differentially expressed. Functional annotation and GO term enrichment was performed using the DAVID/EASE Hosack et al., 2003) web application. The normalized enrichment score reflects the degree of over-representation of a gene set at the top or bottom of a ranked list of genes, which is then normalized to account for the size of the set and underlying correlations. Quantitative-PCR analysis on Trp53 (Mm01731290_g1; Applied Biosystems) was performed to check and verify Trp53 gene expression in the different genotypes.
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